Beta Bionics [BBNX] vs Abbott Laboratories [ABT] Detailed Stock Comparison

Beta Bionics Inc.

NASDAQ
Loading...

Abbott Laboratories

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Beta Bionics Inc. wins in 5 metrics, Abbott Laboratories wins in 12 metrics, with 0 ties. Abbott Laboratories appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Beta Bionics Inc. Abbott Laboratories Better
P/E Ratio (TTM) -6.17 25.97 Abbott Laboratories
Price-to-Book Ratio 1.88 3.09 Beta Bionics Inc.
Debt-to-Equity Ratio 2.55 26.79 Beta Bionics Inc.
PEG Ratio 0.13 -1.41 Beta Bionics Inc.
EV/EBITDA -4.20 13.74 Abbott Laboratories
Profit Margin (TTM) -60.27% 13.90% Abbott Laboratories
Operating Margin (TTM) -87.86% 16.50% Abbott Laboratories
EBITDA Margin (TTM) N/A 16.50% N/A
Return on Equity -22.71% 12.36% Abbott Laboratories
Return on Assets (TTM) -15.04% 7.52% Abbott Laboratories
Free Cash Flow (TTM) $-56.22M $7.40B Abbott Laboratories
Dividend Yield N/A 1.97% N/A
1-Year Return -29.70% -35.92% Beta Bionics Inc.
Price-to-Sales Ratio (TTM) 4.62 3.57 Abbott Laboratories
Enterprise Value $316.73M $166.96B Abbott Laboratories
EV/Revenue Ratio 2.87 3.70 Beta Bionics Inc.
Gross Profit Margin (TTM) 59.50% N/A N/A
Revenue per Share (TTM) $3 $26 Abbott Laboratories
Earnings per Share (Diluted) $-1.37 $3.57 Abbott Laboratories
Beta (Stock Volatility) N/A 0.78 N/A
Short % of Float 17.13% 1.53% Abbott Laboratories

Beta Bionics Inc. vs Abbott Laboratories Stock Performance Analysis

Loading Price Chart...

BBNX
ABT

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Beta Bionics Inc.-2.66%7.05%21.82%7.61%-59.05%-57.44%
Abbott Laboratories0.02%1.53%-0.63%-23.43%-30.57%-29.95%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Beta Bionics Inc.-29.70%-49.10%-49.10%-49.10%-49.10%-49.10%
Abbott Laboratories-35.92%-17.85%-21.68%118.48%249.25%313.73%

Performance & Financial Health Analysis: Beta Bionics Inc. vs Abbott Laboratories

MetricBBNXABT
Market Information
Market Cap i$497.75M$160.70B
Market Cap CategorySmall capLarge cap
10 Day Avg. Volume i1,578,61813,495,583
90 Day Avg. Volume i1,188,16912,934,461
Last Close$12.45$86.99
52 Week Range$8.80 - $32.71$81.97 - $139.06
% from 52W High-61.94%-37.44%
All-Time High$32.71 (Nov 26, 2025)$142.60 (Dec 27, 2021)
% from All-Time High-61.94%-39.00%
Growth Metrics
Quarterly Revenue Growth0.57%0.08%
Quarterly Earnings Growth0.57%-0.19%
Financial Health
Profit Margin (TTM) i-0.60%0.14%
Operating Margin (TTM) i-0.88%0.17%
Return on Equity (TTM) i-0.23%0.12%
Debt to Equity (MRQ) i2.5526.79
Cash & Liquidity
Book Value per Share (MRQ)$6.09$30.02
Cash per Share (MRQ)$4.48$5.14
Operating Cash Flow (TTM) i$-54,782,000$10.80B
Levered Free Cash Flow (TTM) i$-44,055,752$13.77B
Dividends
Last 12-Month Dividend Yield iN/A1.97%
Last 12-Month Dividend iN/A$2.40

Valuation & Enterprise Metrics Analysis: Beta Bionics Inc. vs Abbott Laboratories

MetricBBNX (Apr 26, 2026)ABT (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i-6.1725.97
Forward P/E i-5.6715.29
PEG Ratio i0.13-1.41
Price to Sales (TTM) i4.623.57
Price to Book (MRQ) i1.883.09
Market Capitalization
Market Capitalization i$497.75M$160.70B
Enterprise Value i$316.73M$166.96B
Enterprise Value Metrics
Enterprise to Revenue i2.873.70
Enterprise to EBITDA i-4.2013.74
Risk & Other Metrics
Beta iN/A0.78
Book Value per Share (MRQ) i$6.09$30.02

Financial Statements Comparison: Beta Bionics Inc. vs Abbott Laboratories

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricBBNX (2025)ABT (2025)
Revenue/Sales i100.25M44.33B
Cost of Goods Sold i44.71M19.32B
COGS % of Revenue i44.6%43.6%
Gross Profit i55.54M25.01B
Gross Margin i55.4%56.4%
Research & Development i34.79M2.94B
Operating Income (EBIT) i-71.68M8.05B
Operating Margin i-71.5%18.2%
EBITDA i-56.36M12.03B
EBITDA Margin i-56.2%27.1%
Pre-Tax Income i-73.20M8.47B
Pre-Tax Income % of Revenue i-73.0%19.1%
Income Tax iN/A1.94B
Income Tax % of Revenue i0.0%4.4%
Net Income (Profit) i-73.20M6.52B
Profit Margin i-73.0%14.7%

Balance Sheet & Liquidity Metrics

MetricBBNX (2025)ABT (2025)
Cash & Equivalents i31.58M8.52B
Total Current Assets i267.91M26.00B
Total Current Assets % of Revenue i267.2%58.6%
Total Current Liabilities i30.92M16.50B
Total Current Liabilities % of Revenue i30.8%37.2%
Long-Term Debt i5.37M10.83B
Long-Term Debt % of Revenue i5.4%24.4%
Total Shareholders Equity i287.61M52.77B
Retained Earnings i-369.94M49.78B
Retained Earnings % of Revenue i-369.0%112.3%
Property, Plant & Equipment i15.87M17.57B

Cash Flow Statement Comparison

MetricBBNX (2025)ABT (2025)
Operating Cash Flow i-66.54M10.80B
Operating Cash Flow % of Revenue i-66.4%24.4%
Capital Expenditures i-5.30M-2.17B
Free Cash Flow i-56.22M7.40B
FCF Margin i-56.1%16.7%
Debt Repayment iN/A-1.50B
Common Stock Repurchase iN/A-893.00M

Short Interest & Institutional Ownership Analysis

MetricBBNXABT
Shares Short i7.60M23.83M
Short Ratio i6.631.93
Short % of Float i17.13%1.53%
Shares Outstanding i44.56M1.74B
Float Shares i23.68M1.73B
% Held by Insiders i0.97%0.54%
% Held by Institutions i109.48%82.23%
% Held by Public i-10.45%17.23%

Dividend Analysis & Yield Comparison: Beta Bionics Inc. vs Abbott Laboratories

MetricBBNXABT
Last 12-Month Dividend iN/A$2.40
Last 12-Month Dividend Yield iN/A1.97%
3-Year Avg Annual Dividend iN/A$2.24
3-Year Avg Dividend Yield iN/A0.50%
3-Year Total Dividends iN/A$6.72
Ex-Dividend DateN/AJan 15, 2026